Lamotrigine Tablets 25 mg + Lamotrigine
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fasting State
Conditions
Fasting State
Trial Timeline
Mar 1, 2012 → May 1, 2012
NCT ID
NCT01618799About Lamotrigine Tablets 25 mg + Lamotrigine
Lamotrigine Tablets 25 mg + Lamotrigine is a phase 1 stage product being developed by Ipca Laboratories for Fasting State. The current trial status is completed. This product is registered under clinical trial identifier NCT01618799. Target conditions include Fasting State.
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01618825 | Phase 1 | Completed |
| NCT01618799 | Phase 1 | Completed |
Competing Products
20 competing products in Fasting State